FIELD: medicine.
SUBSTANCE: invention refers to medicine and concerns an agent inhibiting mitochondrial synthase of nitrogen oxide, representing an ether of L-nitroarginine cationic type, namely, choline ester of L-nitroarginine, carnitine ether of L-nitroarginine, triphenylphosphonium hexyl ether of L-nitroarginine.
EFFECT: invention provides better survival rate in comparison with the prototype (6-Nitroindazole) of experimental animals with cerebrovascular disorders, later onset of cramps and considerable increase in lifetime of experimental animals in hypercapnic hypoxia.
1 cl, 3 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CATIONIC TETRAPEPTIDE Phe-D-Arg-Phe-Lys-NH AS MITOCHONDRIAL NITROGEN OXIDE SYNTHASE INHIBITOR | 2015 |
|
RU2587062C1 |
| THERAPEUTIC PREPARATION AT SPASMODIC SYNDROME | 2001 |
|
RU2191017C1 |
| METHOD FOR DETECTING ACTIVITY AND FUNCTIONAL STATE OF NITROGEN OXIDE SYNTHETASE | 2001 |
|
RU2202110C1 |
| COMPOSITION POSSESSING ENDOTHELIAL PROTECTIVE, VASODILATING AND ANGIOPROTECTIVE EFFECT | 2011 |
|
RU2464019C1 |
| METHOD FOR SIMULATION OF ENDOTHELIAL DYSFUNCTION ASSOCIATED WITH LOW GRADATION SYSTEMIC INFLAMMATION AND OXIDATIVE STRESS | 2016 |
|
RU2618657C1 |
| METHOD FOR CORRECTION OF OXIDATIVE STRESS AND NO PRODUCING ENDOTHELIAL DYSFUNCTION ACCOMPANYING VASCULAR COMPLICATIONS OF DIABETES MELLITUS IN EXPERIMENT | 2013 |
|
RU2521279C1 |
| BIODEGRADABLE ARGININE-CONTAINING POLYMERS | 2014 |
|
RU2549908C1 |
| COMBINATION OF INHIBITORS OF NO-SYNTHETASE AND SCAVENGERS OF OXYGEN REACTIVE SPECIES | 1997 |
|
RU2174844C2 |
| METHOD FOR SIMULATING ENDOTHELIAL DYSFUNCTION AND PATHOLOGY OF INTERNAL ORGANS IN EXPERIMENT | 2019 |
|
RU2712102C1 |
| APPLICATION OF CITOFLAVIN FOR TREATMENT OF TICK-BORNE NEUROINFECTIONS | 2007 |
|
RU2342131C2 |
